Improving treatment for Parkinson's disease: Harnessing photothermal and phagocytosis-driven delivery of levodopa nanocarriers across the blood-brain barrier

Improving treatment for Parkinson's disease: Harnessing photothermal and phagocytosis-driven delivery of levodopa nanocarriers across the blood-brain barrier

Parkinson's disease (PD) poses a significant therapeutic challenge, mainly due to the limited ability of drugs to cross the blood-brain barrier (BBB) without undergoing metabolic transformations. Levodopa, a key component of dopamine replacement therapy, effectively enhances dopaminergic activi...

Full description

Saved in:

Bibliographic Details
Main Authors:	Kaili Liang, Li Yang, Jiawei Kang, Bo Liu, Ding Zhang, Liyan Wang, Wei Wang, Qing Wang
Format:	Article
Language:	English
Published:	Elsevier 2024-12-01
Series:	Asian Journal of Pharmaceutical Sciences
Subjects:	Levodopa Oxidative stress Blood-brain barrier Photothermal effect Phagocytosis
Online Access:	http://www.sciencedirect.com/science/article/pii/S1818087624000801
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Discinesias induzidas por levodopa em 176 pacientes com doença de Parkinson Levodopa-induced dyskinesias in 176 parkisonian patients
by: Maria Sheila G. Rocha, et al.
Published: (1995-12-01)

Hyponatremia in Parkinson’s Disease: The Impact of Carbidopa-Levodopa Therapy
by: Elizabeth Schumacher, et al.
Published: (2025-06-01)

Prosody and levodopa in Parkinsons disease
by: Luciana Lemos de Azevedo, et al.
Published: (2013-11-01)

Diagnostic prediction model for levodopa-induced dyskinesia in Parkinson’s disease
by: Bruno Lopes SANTOS-LOBATO, et al.
Published: (2020-04-01)

Low serum uric acid levels and levodopa-induced dyskinesia in Parkinson's disease
by: Nayron Medeiros Soares, et al.
Published: (2023-01-01)

Contribution of dopaminergic polymorphisms to levodopa treatment response and drug concentration in Chinese patients with Parkinson’s disease
by: Xiaoqin He, et al.
Published: (2025-01-01)

Effect of levodopa on interleukin-15 and RANTES circulating levels in patients affected by Parkinson's disease
by: Sebastiano Gangemi, et al.
Published: (2003-01-01)

Working memory in Parkinson's disease patients: clinical features and response to levodopa Memória de trabalho em pacientes com doença de Parkinson: características clínicas e resposta a levodopa
by: Rogério Beato, et al.
Published: (2008-06-01)

Levodopa-induced motor complications associated with benserazide and carbidopa in Parkinson’s disease: a disproportionality analysis of the FAERS database
by: Huaide Qiu, et al.
Published: (2025-03-01)

Experience in using levodopa-benserazide
by: Elena Anatolyevna Katunina, et al.
Published: (2015-10-01)

Efficacy and motor complications of original and generic levodopa in Parkinson&#39;s disease treatment
by: Kasemsap N, et al.
Published: (2016-05-01)

Development and study of mucoadhesive microcapsules for the nasal levodopa delivery
by: D. S. Gordeeva, et al.
Published: (2024-11-01)

Executive dysfunctions impair and levodopa improves articulatory timing in Parkinson‘s disease
by: Elisa Herbig, et al.
Published: (2025-07-01)

How to dose extended-release carbidopa-levodopa capsules (IPX203, CREXONT®) in patients with Parkinson’s disease
by: Robert A. Hauser, et al.
Published: (2025-01-01)

Symptom improvement in a South Asian patient with Parkinson’s disease treated with immediate- and extended-release carbidopa–levodopa: a case report
by: Gail Reiner, et al.
Published: (2025-07-01)

Effect of vibrio cholerae enterotoxin on phagocytosis in vitro
by: Baghdad Science Journal
Published: (2010-09-01)

Quality of life scale in parkinson's disease PDQ-39 - (Brazilian Portuguese version) to assess patients with and without levodopa motor fluctuation Escala para qualidade de vida na doença de Parkinson - PDQ 39 (versão do Português falado no Brasil) como instrumento para avaliação de pacientes com e sem flutuação motora decorrente da levodopa
by: Renata Guzzo Souza, et al.
Published: (2007-09-01)

Levodopa induces thyroid function regulation in a patient with thyroid hormone resistance and Parkinson’s disease: a case report
by: Gabriela Rozo-Paz, et al.
Published: (2025-03-01)

Pain in Parkinson's disease Dor na doença de Parkinson
by: Grace Helena Letro, et al.
Published: (2009-09-01)

Evaluation of the potential therapeutic effect of africanized honeybee venom (Apis mellifera Linnaeus) on levodopa-induced dyskinesias in mice
by: CAMILA G. DANTAS, et al.
Published: (2025-06-01)

Harbinger of storm: influence of Oliver Sacks on levodopa therapy in early 1970s
by: Bruno Lopes dos Santos-Lobato, et al.
Published: (2016-08-01)

Inefficacy of Repetitive Transcranial Magnetic Stimulation in Parkinson’s Disease Patients with Levodopa-Induced Dyskinesias: Results from a Pilot Study
by: Alma Medrano-Hernández, et al.
Published: (2025-07-01)

Efficacy and safety of levodopa in secondary dystonia due to neurological Wilson disease (LIDWID)
by: Jayantee Kalita, et al.
Published: (2025-01-01)

Irisin alleviated sepsis via enhancing macrophage phagocytosis and reducing inflammation levels
by: Zeen Gong, et al.
Published: (2025-08-01)

USE OF THREE-COMPONENT LEVODOPA (LEVODOPA/CARBIDOPA/ENTACAPONE) TO CORRECT NOCTURNAL SYMPTOMS OF PARKINSON,S DISEASE
by: T. K. Kulua, et al.
Published: (2015-08-01)

Consequences of internalization and phagocytosis of Listeria during an infectious process
by: Yu. N. Odintsov, et al.
Published: (2003-12-01)

Inhibition of levodopa metabolism to dopamine by honokiol short-chain fatty acid derivatives may enhance therapeutic efficacy in Parkinson’s disease
by: Gang Cheng, et al.
Published: (2025-06-01)

Chiral‐induced highly efficient NIR–photothermal conversion of perylene diimide@silica nanocapsules for photothermal therapy
by: Yue Zhao, et al.
Published: (2024-12-01)

The Influence of pH on the Catalytic Capacity of Levodopa in the Electroreduction Processes of Zn<sup>2+</sup> Ions
by: Jolanta Nieszporek, et al.
Published: (2025-06-01)

Phylogenetic analysis of pathogenic algae reveals lineage-dependent patterns of phagocytosis
by: Christopher D. Shave, et al.
Published: (2025-06-01)

Continuous Dopaminergic Stimulation-Based Levodopa Treatment in Patients with Early to Mid-Stage Parkinson’s Disease: A Systematic Review and Meta-Analysis
by: Rong Tang, et al.
Published: (2025-05-01)

Effect of levodopa and clioquinol on antioxidant capacity in Parkinson’s disease rhesus monkeys
by: LI Like, et al.
Published: (2017-05-01)

Analytical method for simultaneous quantification of levodopa and carbidopa in the injectable oleogel formulation by HPLC
by: Deepa D. Nakmode, et al.
Published: (2025-02-01)

Complement activation drives the phagocytosis of necrotic cell debris and resolution of liver injury
by: Sofie Vandendriessche, et al.
Published: (2024-12-01)

Microglial phagocytosis of living photoreceptors contributes to inherited retinal degeneration
by: Lian Zhao, et al.
Published: (2015-07-01)

SUMOylation Regulates Neutrophil Phagocytosis and Migration
by: Ran Zhang, et al.
Published: (2025-07-01)

How I treat Parkinson's disease
by: Egberto Reis Barbosa, et al.
Published: (2022-08-01)

Nanoagent-Mediated Photothermal Therapy: From Delivery System Design to Synergistic Theranostic Applications
by: Shang Y, et al.
Published: (2025-05-01)

Synergistic action of propolis with levodopa in the management of Parkinsonism in Drosophila melanogaster
by: Herbert Izo, Ninsiima, et al.
Published: (2020)

Levodopa and pramipexole combination therapy efficacy in Vietnamese patients with Parkinson’s disease: a randomized controlled trial
by: Minh Van Le, et al.
Published: (2024-03-01)